Search
Close this search box.

We are creating some awesome events for you. Kindly bear with us.

HKSTP partner firm shares latest progress in HealthTech

Image Credits: HKSTP, Press Release

According to a recent press release, an HKSTP partner company, shared the latest progress of the company’s innovative biological drug, BCT-100, which is aimed at treating cancer.

Beyond the positive results seen for cancer treatment, the drug has also shown immunosuppressive properties that can be used to treat autoimmune diseases such as rheumatoid arthritis. These results from BCT marked a milestone for the biotech industry in Hong Kong.

The drug was the first Hong Kong-developed innovative drug approved for clinical trials by the US Food and Drug Administration (FDA). BCT-100 targets arginine auxotrophic cancers, such as acute myeloid leukaemia, melanoma, hepatocellular carcinoma and prostate cancer.

BCT has already confirmed the PK/PD and safety of BCT-100 in the US clinical study, and the company is now recruiting more cases for the phase I extension to confirm drug efficacy in melanoma.

Phase I of the study saw a substantial number of stable diseases among prostate cancer patients. The team is also actively verifying the application of a proprietary biomarker panel, which can help identify other cancer patients who can benefit the most from BCT-100 treatment.

The eligible patient population is expected to be expanded by multiple folds soon. Once the phase I extension study is completed by Q4, the firm will move on to a multi-centre phase IIb/III in the US.

While in Hong Kong, the firm will seek a listing on the Stock Exchange of Hong Kong as a pre-revenue biotech company and are actively planning on such a public offering in 2020.

Overseas studies from several reputed universities have presented new data that showed that the drug is also effective in treating autoimmune diseases.

HKSTP’s support to BCT with all-rounded facilities for over 10 years

BCT joined Hong Kong Science Park in 2007. With its decade-long history in biopharmaceutical R&D, as well as advanced laboratory facilities and support services, BCT successfully developed a drug candidate in active phase II clinical trials and received support from renowned venture funds.

The Chief Technology Officer of HKSTP noted that the Park and its members and leadership are all happy to see new progress in BCT’s R&D work. Biomedical technology is one of the Park’s fastest growing clusters with 115 partner companies and incubatees based in Hong Kong Science Park.

HKSTP is committed to contributing to their success by providing comprehensive R&D infrastructure and support services to accelerate translational research and commercialization.

The hope is to see more advanced biotech companies join the HKSTP ecosystem to help build a better future for the biotech industry in Hong Kong.

As far as Hong Kong’s Smart City initiatives go, the HKSAR Government has stated that one of its missions is to make people happier, healthier, smarter and more prosperous, and the city greener, cleaner, more livable, sustainable, resilient and competitive.

Moreover, the HKSAR leadership aims to promote healthy living and ageing in different settings, including hospitals, care homes and ultimately in the community.

The Government seeks to enable research, like BCT-100. through by facilitating healthcare-related research in 2019 and start adopting a smart hospital approach. By 2020 it is hoped that the use of an automatic system interface with vital sign devices or hospital navigation applications will be piloted in new hospital projects.

The work by the HKSTP partner company will help realise the Smart City goal of enabling citizens to enjoy healthcare services supported by new technology applications.

PARTNER

Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.

PARTNER

As a Titanium Black Partner of Dell Technologies, CTC Global Singapore boasts unparalleled access to resources.

Established in 1972, we bring 52 years of experience to the table, solidifying our position as a leading IT solutions provider in Singapore. With over 300 qualified IT professionals, we are dedicated to delivering integrated solutions that empower your organization in key areas such as Automation & AI, Cyber Security, App Modernization & Data Analytics, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Renowned for our consulting expertise and delivering expert IT solutions, CTC Global Singapore has become the preferred IT outsourcing partner for businesses across Singapore.

PARTNER

Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit www.planview.com.

SUPPORTING ORGANISATION

SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.

PARTNER

HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 

PARTNER

IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.